Abstract
Allergic rhinitis (AR) is one of the most common diseases affecting adults and children. AR is often a part of a systemic inflammatory process associated with other inflammatory conditions, including allergic conjunctivitis (Ac), rhinosinusitis and asthma. Undertreated AR impairs quality of life, exacerbates asthma and is a major factor in asthma development. There is a strong recommendation that clinicians recommend intranasal steroids (INS) for patients with a clinical diagnosis of AR whose symptoms affect their quality of life. All modern INS are minimally bioavailable and similar with regard to efficacy and safety at the recommended starting dose. however, differences in patient preference and safety of use during pregnancy may contribute to primary care physicians’ selection of an INS therapy for their patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
